Compared to a net loss of Rs 12 crore in FY25, the pharma major reported a consolidated turnaround in its financial performance
The transaction marks a clear portfolio reshuffle for Indoco
His appointment is expected to further strengthen the company’s financial governance and regional operational strategy across South Asia
Reshaped by COVID-19, rising test demand, and a shift toward decentralized diagnostics, qPCR has evolved from niche academic use to a core clinical engine
Strong CDMO growth, improved product mix and operational leverage drive profitability expansion
Pharma and biotech infrastructure firm targets 25–30% growth as Middle East and Africa emerge as key expansion markets
In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth
Acquisition enhances integrated pharmacovigilance platform, combining AI, automation, and services to improve compliance, efficiency, and end-to-end clinical safety operations
Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities
Subscribe To Our Newsletter & Stay Updated
